Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Jun 15;99(12):2858–2866. doi: 10.1172/JCI119479

Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice.

S H Zhang 1, R L Reddick 1, E Avdievich 1, L K Surles 1, R G Jones 1, J B Reynolds 1, S H Quarfordt 1, N Maeda 1
PMCID: PMC508136  PMID: 9185508

Abstract

Dietary administration of probucol (0.5%, wt/wt) efficiently reduced total plasma cholesterol levels in apolipoprotein E-deficient mice (apoE-/-) by 40%, with decreases in high density lipoprotein (HDL) and apoAI by 70 and 50%, respectively. Paradoxically, however, aortic atherosclerotic plaques in the probucol-treated apoE-/- mice formed more rapidly than in the untreated apoE-/- mice, and the lesions were two to four times larger and more mature regardless of sex, age, and genetic background (P < 10(-)6). Histologically, lesions in probucol-treated mice contained increased fibrous materials and cells other than foam cells, and were commonly associated with focal inflammation and aneurysmal dilatation. Probucol treatment also accelerated lesion development in apoE+/- mice fed an atherogenic diet, indicating that the adverse effect is not dependent on the complete absence of apoE. Furthermore, mice lacking apoE and apoAI have plasma lipoprotein profiles very similar to the probucol-treated apoE-/- mice, but do not have accelerated plaque development. Thus, the enhanced atherosclerosis in the probucol-treated animals is unlikely to be caused by the reduction of HDL and apoAI levels. Our data indicate that a reduction in plasma cholesterol caused by probucol does not necessarily lead to an antiatherogenic effect.

Full Text

The Full Text of this article is available as a PDF (462.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atmeh R. F., Stewart J. M., Boag D. E., Packard C. J., Lorimer A. R., Shepherd J. The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins. J Lipid Res. 1983 May;24(5):588–595. [PubMed] [Google Scholar]
  2. Baker S. G., Joffe B. I., Mendelsohn D., Seftel H. C. Treatment of homozygous familial hypercholesterolaemia with probucol. S Afr Med J. 1982 Jul 3;62(1):7–11. [PubMed] [Google Scholar]
  3. Beynen A. C. Discrepancies between the outcome of animal and human studies on the mode of action of probucol. Atherosclerosis. 1986 Sep;61(3):249–251. doi: 10.1016/0021-9150(86)90146-2. [DOI] [PubMed] [Google Scholar]
  4. Björkhem I., Henriksson-Freyschuss A., Breuer O., Diczfalusy U., Berglund L., Henriksson P. The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler Thromb. 1991 Jan-Feb;11(1):15–22. doi: 10.1161/01.atv.11.1.15. [DOI] [PubMed] [Google Scholar]
  5. Braesen J. H., Beisiegel U., Niendorf A. Probucol inhibits not only the progression of atherosclerotic disease, but causes a different composition of atherosclerotic lesions in WHHL-rabbits. Virchows Arch. 1995;426(2):179–188. doi: 10.1007/BF00192640. [DOI] [PubMed] [Google Scholar]
  6. Callow M. J., Verstuyft J., Tangirala R., Palinski W., Rubin E. M. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest. 1995 Sep;96(3):1639–1646. doi: 10.1172/JCI118203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Daugherty A., Zweifel B. S., Schonfeld G. The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits. Br J Pharmacol. 1991 May;103(1):1013–1018. doi: 10.1111/j.1476-5381.1991.tb12293.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Elinder L. S., Hådell K., Johansson J., Mølgaard J., Holme I., Olsson A. G., Walldius G. Probucol treatment decreases serum concentrations of diet-derived antioxidants. Arterioscler Thromb Vasc Biol. 1995 Aug;15(8):1057–1063. doi: 10.1161/01.atv.15.8.1057. [DOI] [PubMed] [Google Scholar]
  9. France D. S., Hughes T. E., Miserendino R., Spirito J. A., Babiak J., Eskesen J. B., Tapparelli C., Paterniti J. R., Jr Nonimmunochemical quantitation of mammalian apolipoprotein A-I in whole serum or plasma by nonreducing gel electrophoresis. J Lipid Res. 1989 Dec;30(12):1997–2004. [PubMed] [Google Scholar]
  10. Gordon D. J., Rifkind B. M. High-density lipoprotein--the clinical implications of recent studies. N Engl J Med. 1989 Nov 9;321(19):1311–1316. doi: 10.1056/NEJM198911093211907. [DOI] [PubMed] [Google Scholar]
  11. Hayek T., Chajek-Shaul T., Walsh A., Azrolan N., Breslow J. L. Probucol decreases apolipoprotein A-I transport rate and increases high density lipoprotein cholesteryl ester fractional catabolic rate in control and human apolipoprotein A-I transgenic mice. Arterioscler Thromb. 1991 Sep-Oct;11(5):1295–1302. doi: 10.1161/01.atv.11.5.1295. [DOI] [PubMed] [Google Scholar]
  12. Ishibashi S., Goldstein J. L., Brown M. S., Herz J., Burns D. K. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 1994 May;93(5):1885–1893. doi: 10.1172/JCI117179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Ooshima A., Yoshida H., Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5928–5931. doi: 10.1073/pnas.84.16.5928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Nagano Y., Nakamura T., Matsuzawa Y., Cho M., Ueda Y., Kita T. Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit--long-term antiatherogenic effect and effects on established plaques. Atherosclerosis. 1992 Feb;92(2-3):131–140. doi: 10.1016/0021-9150(92)90272-i. [DOI] [PubMed] [Google Scholar]
  15. Nakashima Y., Plump A. S., Raines E. W., Breslow J. L., Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994 Jan;14(1):133–140. doi: 10.1161/01.atv.14.1.133. [DOI] [PubMed] [Google Scholar]
  16. Naruszewicz M., Carew T. E., Pittman R. C., Witztum J. L., Steinberg D. A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit. J Lipid Res. 1984 Nov;25(11):1206–1213. [PubMed] [Google Scholar]
  17. Nestel P. J., Billington T. Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis. Atherosclerosis. 1981 Jan-Feb;38(1-2):203–209. doi: 10.1016/0021-9150(81)90117-9. [DOI] [PubMed] [Google Scholar]
  18. Paigen B., Morrow A., Holmes P. A., Mitchell D., Williams R. A. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987 Dec;68(3):231–240. doi: 10.1016/0021-9150(87)90202-4. [DOI] [PubMed] [Google Scholar]
  19. Parthasarathy S., Young S. G., Witztum J. L., Pittman R. C., Steinberg D. Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest. 1986 Feb;77(2):641–644. doi: 10.1172/JCI112349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Piedrahita J. A., Zhang S. H., Hagaman J. R., Oliver P. M., Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4471–4475. doi: 10.1073/pnas.89.10.4471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Plump A. S., Smith J. D., Hayek T., Aalto-Setälä K., Walsh A., Verstuyft J. G., Rubin E. M., Breslow J. L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992 Oct 16;71(2):343–353. doi: 10.1016/0092-8674(92)90362-g. [DOI] [PubMed] [Google Scholar]
  22. Purcell-Huynh D. A., Farese R. V., Jr, Johnson D. F., Flynn L. M., Pierotti V., Newland D. L., Linton M. F., Sanan D. A., Young S. G. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest. 1995 May;95(5):2246–2257. doi: 10.1172/JCI117915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Reddick R. L., Zhang S. H., Maeda N. Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. Arterioscler Thromb. 1994 Jan;14(1):141–147. doi: 10.1161/01.atv.14.1.141. [DOI] [PubMed] [Google Scholar]
  24. Regnström J., Walldius G., Nilsson S., Elinder L. S., Johansson J., Mölgaard J., Holme I., Olsson A. G., Nilsson J. The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclerosis. 1996 Sep 6;125(2):217–229. [PubMed] [Google Scholar]
  25. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801–809. doi: 10.1038/362801a0. [DOI] [PubMed] [Google Scholar]
  26. Sasahara M., Raines E. W., Chait A., Carew T. E., Steinberg D., Wahl P. W., Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest. 1994 Jul;94(1):155–164. doi: 10.1172/JCI117301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Schwartz C. J., Valente A. J., Sprague E. A., Kelley J. L., Nerem R. M. The pathogenesis of atherosclerosis: an overview. Clin Cardiol. 1991 Feb;14(2 Suppl 1):I1–16. doi: 10.1002/clc.4960141302. [DOI] [PubMed] [Google Scholar]
  28. Shankar R., Sallis J. D., Stanton H., Thomson R. Influence of probucol on early experimental atherogenesis in hypercholesterolemic rats. Atherosclerosis. 1989 Aug;78(2-3):91–97. doi: 10.1016/0021-9150(89)90212-8. [DOI] [PubMed] [Google Scholar]
  29. Stein Y., Stein O., Delplanque B., Fesmire J. D., Lee D. M., Alaupovic P. Lack of effect of probucol on atheroma formation in cholesterol-fed rabbits kept at comparable plasma cholesterol levels. Atherosclerosis. 1989 Feb;75(2-3):145–155. doi: 10.1016/0021-9150(89)90171-8. [DOI] [PubMed] [Google Scholar]
  30. Steinberg D. Studies on the mechanism of action of probucol. Am J Cardiol. 1986 Jun 27;57(16):16H–21H. doi: 10.1016/0002-9149(86)90430-3. [DOI] [PubMed] [Google Scholar]
  31. Tangirala R. K., Casanada F., Miller E., Witztum J. L., Steinberg D., Palinski W. Effect of the antioxidant N,N'-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in apoE-deficient mice. Arterioscler Thromb Vasc Biol. 1995 Oct;15(10):1625–1630. doi: 10.1161/01.atv.15.10.1625. [DOI] [PubMed] [Google Scholar]
  32. Tawara K., Tomikawa M., Abiko Y. Mode of action of probucol in reducing serum cholesterol in mice. Jpn J Pharmacol. 1986 Jan;40(1):123–133. doi: 10.1254/jjp.40.123. [DOI] [PubMed] [Google Scholar]
  33. Walldius G., Erikson U., Olsson A. G., Bergstrand L., Hådell K., Johansson J., Kaijser L., Lassvik C., Mölgaard J., Nilsson S. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol. 1994 Nov 1;74(9):875–883. doi: 10.1016/0002-9149(94)90579-7. [DOI] [PubMed] [Google Scholar]
  34. Warnick G. R., Benderson J., Albers J. J. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982 Jun;28(6):1379–1388. [PubMed] [Google Scholar]
  35. Williamson R., Lee D., Hagaman J., Maeda N. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7134–7138. doi: 10.1073/pnas.89.15.7134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Yamamoto A., Matsuzawa Y., Yokoyama S., Funahashi T., Yamamura T., Kishino B. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol. 1986 Jun 27;57(16):29H–35H. doi: 10.1016/0002-9149(86)90434-0. [DOI] [PubMed] [Google Scholar]
  37. Zhang S. H., Reddick R. L., Burkey B., Maeda N. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest. 1994 Sep;94(3):937–945. doi: 10.1172/JCI117460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Zhang S. H., Reddick R. L., Piedrahita J. A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992 Oct 16;258(5081):468–471. doi: 10.1126/science.1411543. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES